View Item 

Show simple item record

Endpoints and New Options for Treatment of Chronic Hepatitis D
dc.contributor.authorLok, Anna S.
dc.contributor.authorNegro, Francesco
dc.contributor.authorAsselah, Tarik
dc.contributor.authorFarci, Patrizia
dc.contributor.authorRizzetto, Mario
dc.date.accessioned2021-12-02T02:31:19Z
dc.date.available2023-01-01 21:31:18en
dc.date.available2021-12-02T02:31:19Z
dc.date.issued2021-12
dc.identifier.citationLok, Anna S.; Negro, Francesco; Asselah, Tarik; Farci, Patrizia; Rizzetto, Mario (2021). "Endpoints and New Options for Treatment of Chronic Hepatitis D." Hepatology (6): 3479-3485.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/171027
dc.publisherWiley Periodicals, Inc.
dc.titleEndpoints and New Options for Treatment of Chronic Hepatitis D
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171027/1/hep32082_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171027/2/hep32082.pdf
dc.identifier.doi10.1002/hep.32082
dc.identifier.sourceHepatology
dc.identifier.citedreferenceEtzion O, Hamid SS, Lurie Y, Gane E, Bader N, Yardeni D, et al. End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post‐treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. J Hepatol 2019; 70 ( Suppl. ): e32.
dc.identifier.citedreferenceShekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, et al. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Sci Rep 2020; 10: 7837.
dc.identifier.citedreferenceGlenn JS. Prenylation of HDAg and antiviral drug development. Curr Top Microbiol Immunol 2006; 307: 133 ‐ 149.
dc.identifier.citedreferenceTu T, Urban S. Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Curr Opin Virol 2018; 30: 68 ‐ 79.
dc.identifier.citedreferenceBazinet M, P-ntea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa‐2a for treatment‐naive patients with chronic hepatitis B virus and hepatitis D virus co‐infection (REP 301 and REP 301‐LTF): a non‐randomised, open‐label, phase 2 trial. Lancet Gastroenterol Hepatol 2017; 2: 877 ‐ 889.
dc.identifier.citedreferenceKoh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes‐Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof‐of‐concept randomised, double‐blind, placebo‐controlled phase 2A trial. Lancet Infect Dis 2015; 15: 1167 ‐ 1174.
dc.identifier.citedreferenceBogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol 2016; 65: 490 ‐ 498.
dc.identifier.citedreferenceBazinet M, P-ntea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection. Hepatol Commun 2020; 5: 189 ‐ 202.
dc.identifier.citedreferenceYurdaydin C, Idilman R, Keskin O, Kalkan Ç, Karakaya FM, Çaliskan A, et al. A phase 2 dose‐optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—analysis from the LOWR HDV‐2 study using the Robogene real‐time qPCR HDV RNA assay. J Viral Hepat 2018; 25 (S uppl. 2 ): 10.
dc.identifier.citedreferenceKoh C, Surana P, Han T, Fryzek N, Kapuria D, Etzion O, et al. A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis—end of study results from the LOWR HDV‐3 study. J Hepatol 2017; 66: S101 ‐ S102.
dc.identifier.citedreferenceWedemeyer H, Port K, Deterding K, Wranke A, Kirschner J, Martins EB, et al. A phase 2 dose‐escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV‐4 (LOWR HDV‐4). J Hepatol 2017; 66: S24.
dc.identifier.citedreferenceKoh C, Hercun J, Rahman F, Huang A, Da B & Surana P et al. A phase 2 study of peginterferon lambda, lonafarnib and ritonavir for 24 weeks: end‐of‐treatment results from the LIFT HDV study. The Liver Meeting, October 30, 2020 (oral late breaker L08). https://assets.website‐files.com/5f3d77cd56d46907a50fb8d9/5f9d9c2057efc43f55b78db7_2020%20TLMdX%20Late‐breaking%20Abstracts‐%20Oct%2030.pdf. Accessed May 7, 2021.
dc.identifier.citedreferenceWedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri‐Petersen M, Bremer B, et al. Final results of a multicenter, open‐label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co‐infection. J Hepatol 2018; 68 ( Suppl. ): S3.
dc.identifier.citedreferenceWedemeyer H, Schoeneweis K, Bogomolov PO, Voronka V, Chulanov V, Stepanova T, et al. Final results of a multicenter, open‐label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG‐interferon alpha 2a in patients with chronic HBV/HDV co‐infection. J Hepatol 2019; 70: e81.
dc.identifier.citedreferenceWedemeyer H, Schöneweis K, Bogomolov PO, Chulanov V, Stepanova T, Viacheslav M, et al. 48 weeks of high dose (10 mg) bulevirtide as mono‐therapy or with peginterferon alfa‐2a in patients with chronic HBV/HDV coinfection. J Hepatol 2020; 73: S52 ‐ S53.
dc.identifier.citedreferenceLoglio A, Ferenci P, Uceda Renteria SC, Tham CYL, van Bömmel F, Borghi M, et al. Excellent safety and effectiveness of high‐dose Myrcludex‐B monotherapy administered for 48 weeks in HDV‐related compensated cirrhosis: a case report of 3 patients. J Hepatol 2019; 71: 834 ‐ 839.
dc.identifier.citedreferenceEuropean Medicines Agency. Hepcludex. https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex. Accessed April 15, 2021.
dc.identifier.citedreferenceYuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, et al. RNA interference therapy with ARC‐898 520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B 899 infection. Hepatology 2020; 72: 19 ‐ 31.
dc.identifier.citedreferenceCaviglia GP, Rizzetto M. Treatment of hepatitis D: an unmet medical need. Clin Microbiol Infect 2020; 26: 824 ‐ 827.
dc.identifier.citedreferenceRizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol 2021; 74: 1200 ‐ 1211.
dc.identifier.citedreferenceSureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol 2016; 64 ( 1 Suppl. ): S102 ‐ S116.
dc.identifier.citedreferenceAsselah T, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, et al. Future treatments for hepatitis delta virus infection. Liver Int 2020; 40 ( Suppl. 1 ): 54 ‐ 60.
dc.identifier.citedreferenceWranke A, Hardtke S, Heidrich B, Dalekos G, Yalçin K, Tabak F, et al. Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta. J Viral Hepat 2020; 27: 1359 ‐ 1368.
dc.identifier.citedreferenceMederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, Bock T, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48: 2022 ‐ 2029.
dc.identifier.citedreferenceWedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, et al. Peginterferon alfa‐2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT‐II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis 2019; 19: 275 ‐ 286.
dc.identifier.citedreferenceFarci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long‐term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740 ‐ 1749.
dc.identifier.citedreferenceYurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, et al.; Hepatitis Delta International Network (HDIN). Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol 2019; 70: 1008 ‐ 1015.
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 2017: 370 ‐ 398.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep32082_am.pdf
Size:
402.6KB
Format:
PDF
View/Open
Name:
hep32082.pdf
Size:
353.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.